4.1 Autonomic and Central Nervous System Pharmacology
Key Takeaways
- Autonomic signal transduction is governed by distinct G-protein coupled cascades: Gq (alpha-1, M1, M3, M5) activates PLC/IP3/DAG; Gi (alpha-2, M2, M4) inhibits adenylyl cyclase and lowers cAMP; Gs (beta-1, beta-2, beta-3, D1) stimulates adenylyl cyclase and elevates cAMP.
- Cardioselective beta-1 blockers (e.g., bisoprolol, metoprolol, atenolol) spare beta-2 bronchial receptors at therapeutic doses, whereas non-selective agents (propranolol, nadolol) and intrinsic sympathomimetic activity (ISA) agents (pindolol, acebutolol) have distinct hemodynamic and pulmonary profiles.
- GABA-A receptors are pentameric ligand-gated chloride channels where benzodiazepines increase channel opening frequency, while barbiturates prolong open duration; Z-drugs selectively target the alpha-1 subunit for sedative-hypnotic efficacy.
- Second-generation antipsychotics combine dopamine D2 receptor antagonism with serotonin 5-HT2A antagonism, lowering extrapyramidal symptom (EPS) risks but increasing metabolic liabilities; clozapine requires strict absolute neutrophil count (ANC) hematologic surveillance due to agranulocytosis risk.
- Antiseizure medications act through targeted molecular mechanisms: voltage-gated sodium channel inactivation (phenytoin, carbamazepine, lamotrigine), T-type calcium channel inhibition in thalamocortical neurons (ethosuximide for absence seizures), GABAergic potentiation (valproate, clobazam), and SV2A vesicle binding (levetiracetam).
Last updated: August 2026
4.1 Autonomic and Central Nervous System Pharmacology
The autonomic nervous system (ANS) and central nervous system (CNS) coordinate involuntary physiological homeostasis, neuroendocrine regulation, cognition, and motor control. A thorough mastery of receptor subtype signaling, neurotransmitter life cycles, and neuropharmacological drug actions is a foundational core of the PEBC Evaluating Examination.
1. Autonomic Nervous System Organization and Signal Transduction
The ANS comprises the sympathetic (thoracolumbar) and parasympathetic (craniosacral) divisions, functioning through distinct preganglionic and postganglionic neurotransmitters and receptor superfamilies.
+--------------------------------------------------------------------------------------+
| AUTONOMIC NEUROTRANSMISSION PATHWAYS |
+--------------------------------------------------------------------------------------+
| PARASYMPATHETIC: |
| [CNS] ===(ACh)===> [Ganglionic Nn Receptor] ===(ACh)===> [Effector Muscarinic (M)] |
| |
| SYMPATHETIC: |
| [CNS] ===(ACh)===> [Ganglionic Nn Receptor] ===(NE)===> [Effector Adrenoceptors] |
| | (alpha-1, beta-1, beta-2) |
| +===(ACh)===> [Sweat Glands (M3)] |
| +===(DA)===> [Renal Vasculature(D1)]|
| |
| ADRENAL MEDULLA: |
| [CNS] ===(ACh)===> [Chromaffin Cell Nn] ===> [Epinephrine (80%) + NE (20%) in Blood]|
| |
| SOMATIC MOTOR: |
| [CNS Motoneuron] =========================(ACh)=========================> [Nm / NMJ]|
+--------------------------------------------------------------------------------------+
Adrenoceptor Subtypes and G-Protein Coupling
Adrenoceptors are 7-transmembrane G-protein coupled receptors (GPCRs) responsive to endogenous catecholamines (norepinephrine and epinephrine):
\mathbf{G_q \text{ Coupling (}\alpha_1\text{)}} &\implies \uparrow \text{Phospholipase C (PLC)} \to \uparrow \text{IP}_3 + \text{DAG} \to \uparrow [\text{Ca}^{2+}]_i \to \text{Smooth Muscle Contraction} \\ \mathbf{G_i \text{ Coupling (}\alpha_2\text{)}} &\implies \downarrow \text{Adenylyl Cyclase (AC)} \to \downarrow \text{cAMP} + \downarrow \text{PKA} \to \text{Inhibition of Transmitter Release} \\ \mathbf{G_s \text{ Coupling (}\beta_1, \beta_2, \beta_3\text{)}} &\implies \uparrow \text{Adenylyl Cyclase (AC)} \to \uparrow \text{cAMP} \to \uparrow \text{Protein Kinase A (PKA)} \end{aligned}$$ | Receptor Subtype | Primary G-Protein | Key Anatomical Locations | Primary Physiological Effect | Clinical Agonists / Antagonists | |:---|:---|:---|:---|:---| | **$\alpha_1$** | $G_q$ | Vascular smooth muscle, radial pupillary muscle, prostate, bladder neck | Vasoconstriction ($\uparrow$ SVR, $\uparrow$ BP), mydriasis, urinary sphincter contraction | Agonists: Phenylephrine, midodrine. Antagonists: Prazosin, doxazosin, tamsulosin ($\alpha_{1A}$ selective) | | **$\alpha_2$** | $G_i$ | Presynaptic adrenergic terminals, pancreatic $\beta$-cells, CNS brainstem | $\downarrow$ NE release (negative feedback), $\downarrow$ sympathetic outflow, $\downarrow$ insulin secretion | Agonists: Clonidine, apraclonidine, dexmedetomidine. Antagonists: Yohimbine | | **$\beta_1$** | $G_s$ | Myocardium (SA/AV node, ventricular myocytes), juxtaglomerular cells | $\uparrow$ Heart rate (chronotropy), $\uparrow$ contractility (inotropy), $\uparrow$ AV conduction (dromotropy), $\uparrow$ renin release | Agonists: Dobutamine, isoproterenol. Antagonists: Bisoprolol, metoprolol, atenolol, esmolol | | **$\beta_2$** | $G_s$ | Bronchial smooth muscle, skeletal vascular beds, uterine muscle, liver | Bronchodilation, vasodilation, uterine relaxation (tocolysis), $\uparrow$ glycogenolysis, $\uparrow \text{K}^+$ cellular uptake | Agonists: Salbutamol, formoterol, salmeterol, terbutaline. Antagonists: Propranolol, timolol, nadolol | | **$\beta_3$** | $G_s$ | Adipose tissue, detrusor smooth muscle of urinary bladder | $\uparrow$ Lipolysis, detrusor relaxation (increases bladder storage capacity) | Agonists: Mirabegron, vibegron | ### Cholinergic Receptors: Muscarinic and Nicotinic Subtypes - **Muscarinic GPCRs**: - **$M_1, M_3, M_5$ ($G_q$)**: Mediate exocrine glandular secretion (salivation, lacrimation, sweating), gastrointestinal smooth muscle contraction, bronchial constriction, and pupillary sphincter contraction (miosis). $M_3$ stimulation on vascular endothelial cells stimulates endothelial nitric oxide synthase (eNOS), releasing nitric oxide (NO) and causing paradoxical vasodilation. - **$M_2, M_4$ ($G_i$)**: $M_2$ receptors are localized on the sinoatrial and atrioventricular nodes, opening inward-rectifying $\text{K}^+$ channels ($I_{K,\text{ACh}}$) and decreasing cAMP, producing negative chronotropy, negative dromotropy, and decreased atrial inotropy. - **Nicotinic Ligand-Gated Ion Channels**: - **$N_M$ (Neuromuscular junction)**: Pentameric $(\alpha_1)_2\beta_1\gamma\delta$ ion channels. Acetylcholine binding allows rapid $\text{Na}^+$ influx and $\text{K}^+$ efflux, causing endplate potential depolarization and skeletal muscle contraction. - **$N_N$ (Autonomic ganglia and adrenal medulla)**: Mediates trans-synaptic transmission across all autonomic ganglia. --- ## 2. Autonomic Pharmacology: Therapeutic Drug Classes ``` +--------------------------------------------------------------------------------------+ | AUTONOMIC DRUG CLASSIFICATION MATRIX | +--------------------------------------------------------------------------------------+ | CHOLINERGIC AGENTS: | | - Direct Agonists : Bethanechol (bladder atony), Pilocarpine (glaucoma) | | - AChE Inhibitors : Donepezil, Rivastigmine, Pyridostigmine, Neostigmine | | - Antimuscarinics : Atropine, Ipratropium, Tiotropium, Oxybutynin, Glycopyrrolate| | | | ADRENERGIC AGENTS: | | - Non-Selective Agonists: Epinephrine (alpha-1, alpha-2, beta-1, beta-2), NE | | - Beta-Blockers (Selective): Bisoprolol, Metoprolol, Atenolol (Cardioselective) | | - Beta-Blockers (Non-Sel): Propranolol, Timolol, Nadolol | | - Alpha-Beta Blockers : Carvedilol, Labetalol | | - Alpha-1 Blockers : Tamsulosin (BPH), Prazosin, Doxazosin (Antihypertensive) | +--------------------------------------------------------------------------------------+ ``` ### Neuromuscular Blockers and Reversal Strategies - **Depolarizing Blockers (Succinylcholine)**: Binds $N_M$ receptors and causes persistent endplate depolarization (Phase I block with fasciculations, followed by Phase II desensitization block). Rapid onset ($<60\text{ seconds}$), ultra-short duration ($5-10\text{ minutes}$) metabolized by plasma butyrylcholinesterase (pseudocholinesterase). *Adverse effects*: Hyperkalemia (hazardous in burn, trauma, or spinal denervation patients due to extrajunctional receptor upregulation), malignant hyperthermia (treated with **dantrolene**), and prolonged apnea in atypical pseudocholinesterase variants. - **Non-Depolarizing Blockers (Rocuronium, Vecuronium, Cisatracurium)**: Competitive antagonists at $N_M$ receptors. Cisatracurium undergoes organ-independent **Hofmann elimination** (spontaneous ester hydrolysis and chemical degradation at physiological pH and temperature), making it the agent of choice in severe renal or hepatic impairment. - **Reversal Agents**: - **Sugammadex**: A modified gamma-cyclodextrin that encapsulates and chelates aminosteroid blockers (rocuronium $>$ vecuronium) in plasma at a 1:1 molar ratio, achieving rapid, chemically specific reversal independent of cholinesterase inhibition. - **Neostigmine + Glycopyrrolate**: Neostigmine inhibits AChE to elevate synaptic ACh and competitively displace the blocker; co-administered glycopyrrolate or atropine prevents muscarinic side effects (profound bradycardia, bronchospasm, hypersalivation). --- ## 3. Central Nervous System Pharmacology: Neurotransmitters and Affective Disorders ### GABAergic and Glutamatergic Neurotransmission ``` [GABA-A Receptor: Chloride Ionophore] +---------------------------------+ | Benzodiazepine Site (alpha/gamma)| | GABA Agonist Site (alpha/beta) | | Barbiturate Site (Transmembrane) | | Picrotoxin / Channel Pore | +---------------------------------+ | +------------------------+------------------------+ | | v v [Benzodiazepines: Increase Frequency] [Barbiturates: Increase Duration] - Shift GABA curve to the left - Direct opening at high doses - Flumazenil competitive antagonist - Lower safety margin, respiratory arrest ``` - **$\text{GABA}_A$ Receptor Modulators**: - **Benzodiazepines (Lorazepam, Diazepam, Clonazepam)**: Bind allosterically to the $\alpha/\gamma$ subunit interface, increasing the **frequency** of channel opening in response to GABA. Indicated for acute anxiety, panic disorder, alcohol withdrawal, and status epilepticus. - **Barbiturates (Phenobarbital, Thiopental)**: Increase the **duration** of chloride channel opening and can directly open chloride channels at high concentrations without GABA, explaining their narrow therapeutic index and fatal respiratory depression risks. - **Z-Drugs (Zopiclone, Zolpidem)**: Selective positive allosteric modulators at $\alpha_1$-containing $\text{GABA}_A$ complexes, delivering hypnotic action with minimal anxiolytic or muscle relaxant effects. - **$\text{GABA}_B$ Receptor Agonist (Baclofen)**: Presynaptic $G_i$-coupled GPCR that increases $\text{K}^+$ conductance, hyperpolarizing motor neurons and relieving muscle spasticity. ### Antidepressant Pharmacotherapy (CANMAT Guidelines) According to the Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for Major Depressive Disorder (MDD): | Antidepressant Class | Representative Agents | Primary Mechanism | High-Yield Clinical Pearls & Adverse Effects | |:---|:---|:---|:---|:---| | **SSRIs** | Escitalopram, Sertraline, Fluoxetine, Paroxetine, Citalopram | Selective inhibition of presynaptic Serotonin Transporter (SERT) | First-line MDD; GI upset, sexual dysfunction, insomnia, hyponatremia (SIADH in elderly), QTc prolongation (citalopram max $40\text{ mg/day}$, $20\text{ mg/day}$ if $>60\text{ years}$). Fluoxetine/paroxetine potently inhibit CYP2D6. | | **SNRIs** | Venlafaxine, Duloxetine, Desvenlafaxine | Dual inhibition of SERT and Norepinephrine Transporter (NET) | First-line MDD and neuropathic pain (duloxetine); dose-dependent diastolic hypertension (venlafaxine), discontinuation syndrome upon abrupt cessation. | | **Atypical / Multimodal** | Bupropion, Mirtazapine, Vortioxetine | Bupropion: NET and DAT blocker; Mirtazapine: presynaptic $\alpha_2$ blocker + $5\text{-HT}_2 / 5\text{-HT}_3 / H_1$ antagonist | Bupropion: zero sexual dysfunction, aids smoking cessation, lowers seizure threshold (contraindicated in bulimia/anorexia). Mirtazapine: sedation, marked appetite stimulation and weight gain. | | **TCAs** | Amitriptyline, Nortriptyline, Clomipramine | Non-selective SERT/NET blockade + antagonist at $H_1$, $\alpha_1$, $M_1$, and cardiac fast $I_{\text{Na}}$ | Fatal in overdose due to cardiac conduction blocks, refractory ventricular arrhythmias (prolonged QRS), and hypotension; anticholinergic toxidrome. Clomipramine is gold standard for refractory OCD. | | **MAOIs** | Phenelzine, Tranylcypromine, Moclobemide (RIMA) | Irreversible non-selective MAO-A/B inhibition (phenelzine) or reversible MAO-A inhibition (moclobemide) | Hypertensive crisis when combined with tyramine-rich foods (aged cheeses, draft beers, cured meats). Mandatory $14\text{-day}$ washout when switching to/from other serotonergic agents ($5\text{ weeks}$ for fluoxetine). | --- ## 4. Antipsychotic Pharmacotherapy and Extrapyramidal Syndromes ``` +--------------------------------------------------------------------------------------+ | DOPAMINE PATHWAYS IN ANTIPSYCHOTIC PHARMACOLOGY | +--------------------------------------------------------------------------------------+ | 1. Mesolimbic Pathway : Excess DA = Positive symptoms; D2 block = Antipsychotic | | 2. Mesocortical Pathway : Deficient DA = Negative/cognitive symptoms | | 3. Nigrostriatal Pathway : D2 block = Extrapyramidal Symptoms (EPS) and Tardive Dysk| | 4. Tuberoinfundibular : D2 block = Hyperprolactinemia (galactorrhea, amenorrhea)| +--------------------------------------------------------------------------------------+ ``` ### First-Generation (Typical) vs. Second-Generation (Atypical) Antipsychotics - **First-Generation Antipsychotics (FGAs: Haloperidol, Fluphenazine, Chlorpromazine)**: High-affinity competitive antagonists at dopamine $D_2$ receptors. High-potency agents (haloperidol) carry high rates of extrapyramidal symptoms (EPS) and hyperprolactinemia, but low anticholinergic/sedative liabilities. - **Second-Generation Antipsychotics (SGAs: Olanzapine, Risperidone, Quetiapine, Aripiprazole, Clozapine)**: Combine $D_2$ antagonism with potent **serotonin $5\text{-HT}_{2A}$ antagonism**. $5\text{-HT}_{2A}$ blockade stimulates dopamine release in the nigrostriatal tract, mitigating EPS. - **Aripiprazole / Brexpiprazole / Cariprazine**: Partial agonists at $D_2$ and $5\text{-HT}_{1A}$ receptors, acting as functional stabilizers with low metabolic and EPS liabilities. - **Metabolic Liability Hierarchy**: Clozapine $=$ Olanzapine $>$ Quetiapine $\ge$ Risperidone $>$ Lurasidone $=$ Ziprasidone $=$ Aripiprazole. ### Extrapyramidal Symptom (EPS) Spectrum and Management | EPS Type | Onset Timeline | Clinical Features | Pharmacological Management | |:---|:---|:---|:---|:---| | **Acute Dystonia** | Hours to days | Involuntary spastic muscle contractions (torticollis, oculogyric crisis, trismus, laryngeal spasm) | Anticholinergics: **Benztropine** ($1-2\text{ mg}$ IV/IM) or **Diphenhydramine** ($25-50\text{ mg}$ IV/IM) | | **Akathisia** | Days to weeks | Subjective motor restlessness, irresistible urge to move lower limbs | **Propranolol** ($10-40\text{ mg}$ PO TID) is first-line; dose reduction or switch to quetiapine/aripiprazole | | **Parkinsonism** | Weeks to months | Bradykinesia, cogwheel rigidity, resting tremor, masked facies | Dose reduction, switch to SGA, or add benztropine/amantadine | | **Tardive Dyskinesia** | Months to years | Involuntary choreoathetoid movements of face, tongue (buccolingual masticatory), or trunk | Discontinue anticholinergics; switch to clozapine or quetiapine; VMAT-2 inhibitors (**Valbenazine, Deutetrabenazine**) | | **Neuroleptic Malignant Syndrome (NMS)** | Any time | "Lead-pipe" rigidity, severe hyperthermia, autonomic instability, altered mental status, marked $\uparrow$ CK | Discontinue antipsychotic immediately; ICU admission; **Dantrolene** (ryanodine blocker), **Bromocriptine** (DA agonist) | ### Clozapine Hematologic Surveillance Clozapine is the gold standard for treatment-resistant schizophrenia (failure of $\ge 2$ adequate antipsychotic trials). It is non-EPS-inducing but carries risks of **agranulocytosis** ($<1\%$), severe constipation/ileus, myocarditis, and seizures. - Health Canada and Canadian registry protocols mandate baseline and regular **Absolute Neutrophil Count (ANC)** monitoring: - Mandatory threshold to initiate: $\text{ANC} \ge 2.0 \times 10^9\text{/L}$ (or $\ge 1.5 \times 10^9\text{/L}$ for Benign Ethnic Neutropenia / BEN). - If $\text{ANC} < 1.5 \times 10^9\text{/L}$ (mild/moderate neutropenia): Interrupt therapy and monitor daily. - If $\text{ANC} < 1.0 \times 10^9\text{/L}$ (severe agranulocytosis): Immediately and permanently discontinue clozapine. --- ## 5. Antiseizure Medications (ASMs) and Parkinson's Disease Pharmacotherapy ``` +--------------------------------------------------------------------------------------+ | ANTISEIZURE MEDICATIONS MECHANISM MATRIX | +--------------------------------------------------------------------------------------+ | 1. Voltage-Gated Na+ Channel Blockers: Phenytoin, Carbamazepine, Lamotrigine, Lacosamide | 2. T-Type Ca2+ Channel Blockers : Ethosuximide (Selective for Absence Seizures) | | 3. Alpha-2-Delta Ca2+ Ligands : Gabapentin, Pregabalin (Neuropathic Pain/Adjunct) | 4. SV2A Vesicular Protein Modulators: Levetiracetam, Brivaracetam | | 5. GABAergic Potentiators : Valproic Acid, Clobazam, Vigabatrin, Tiagabine| | 6. Broad-Spectrum Mixed Actions : Valproic Acid, Topiramate, Zonisamide | +--------------------------------------------------------------------------------------+ ``` - **Phenytoin**: Displays non-linear **Michaelis-Menten pharmacokinetics** (hepatic CYP2C9/2C19 saturation within therapeutic range $40-80\text{ }\mu\text{mol/L}$ [$10-20\text{ mg/L}$]). Chronic adverse effects: gingival hyperplasia, hirsutism, peripheral neuropathy, cerebellar ataxia, osteomalacia. Highly protein bound ($90\%$ to albumin). - **Carbamazepine**: Potent enzyme inducer that exhibits **autoinduction** of its own CYP3A4-mediated metabolism over the first $2-4\text{ weeks}$. Adverse effects: hyponatremia (SIADH), aplastic anemia, agranulocytosis, and severe cutaneous adverse reactions (SJS/TEN) strongly linked to the **HLA-B\*1502** allele in Asian ancestry. - **Lamotrigine**: Blocks voltage-gated $\text{Na}^+$ channels and suppresses glutamate release. Metabolized primarily via glucuronidation. *Drug Interaction*: Valproate potently inhibits lamotrigine glucuronidation, doubling its elimination half-life and drastically increasing SJS risk; lamotrigine starting doses must be reduced by $\ge 50\%$. - **Valproic Acid / Divalproex**: Broad-spectrum ASM. Blocks $\text{Na}^+$ channels, increases GABA levels (inhibits GABA transaminase and succinic semialdehyde dehydrogenase), and blocks T-type $\text{Ca}^{2+}$ currents. *Adverse effects*: Hepatotoxicity, acute pancreatitis, hyperammonemia, weight gain, alopecia, thrombocytopenia, and severe **teratogenicity** (neural tube defects; avoid in women of childbearing potential). - **Ethosuximide**: Selectively blocks low-voltage-activated **T-type calcium channels** in thalamocortical relay neurons, disrupting the synchronized $3\text{-Hz}$ spike-and-wave rhythm of **generalized absence seizures**.Test Your Knowledge
A 24-year-old patient who was initiated on intramuscular haloperidol 5 mg for acute psychosis develops severe sustained neck twisting (torticollis) and upward gaze deviation (oculogyric crisis) 18 hours after the second dose. What is the most appropriate immediate pharmacological intervention?
A
B
C
D
Test Your Knowledge
A patient with focal epilepsy maintained on lamotrigine 100 mg daily is diagnosed with bipolar I disorder. The psychiatrist plans to initiate valproic acid. Which pharmacokinetic interaction occurs between these two agents, and what dosage adjustment is required?
A
B
C
D
Test Your Knowledge
A 32-year-old patient with schizophrenia is switched from olanzapine to aripiprazole due to marked weight gain and dyslipidemia. What unique pharmacological receptor profile distinguishes aripiprazole from traditional second-generation antipsychotics?
A
B
C
D
Test Your Knowledge
An 8-year-old child experiences frequent episodes of brief staring spells lasting 5 to 10 seconds during school, accompanied by subtle eyelid fluttering and immediate resumption of activity without postictal confusion. Electroencephalography (EEG) demonstrates characteristic 3-Hz generalized spike-and-wave discharges. Which medication is the first-line pharmacological treatment of choice?
A
B
C
D